Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Rectal Adenocarcinoma

Rectal Adenocarcinoma

14

Pipeline Programs↗

15

Active Trials↗

8

Companies Involved↗

Rectal Adenocarcinoma is an emerging landscape with 14 programs across 8 companies. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

25/100

Mech. Concentration

38/100

Completion Rate

45/100

Attrition Rate

19/100

Pipeline

Programs by Phase

Preclinical1

Raltitrexed

Nanjing Chia-tai Tianqing Pharmaceutical

Phase 1

No programs

Phase 29

Oxaliplatin

Teva

Fluorouracil

Elorac, Inc.

Leucovorin Calcium

Eastern Cooperative Oncology Group

Metronidazole

DePuy Orthopaedics

Adebrelimab

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 34

PD-1 Monoclonal Antibody

Sichuan Baili Pharmaceutical Co., Ltd.

Cetuximab

Imclone

Bevacizumab

Roche

Toripalimab

Coherus Oncology, Inc.

Approved

No programs

Analysis

Modality Breakdown

13programs

Small molecule754%

Monoclonal antibody646%

Modality classified for 100% of 14 pipeline programs.

Analysis

Trial Status

31

clinical trials

Recruiting11 · 35%

Completed5 · 16%

Unknown status5 · 16%

Terminated4 · 13%

Withdrawn2 · 6%

Active, not recruiting2 · 6%

Other2 · 6%

Clinical Trials

Trial Activity

31 trials

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06843434·40 enrolled

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

Recruiting·SSir Run Run Shaw Hospital·Phase 2·NCT06266832·30 enrolled

A Phase II Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04165772·212 enrolled

A Phase II Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06569368·60 enrolled

Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer

Recruiting·OOHSU Knight Cancer Institute·N/A·NCT05081024·50 enrolled

The PRELUDE Study: A Prospective Cohort Study Comparing Neoadjuvant Radiotherapy Followed by Total Mesorectal Excision Versus Upfront Surgery in Patients With Locally Advanced Proximal Rectal Cancer

Recruiting·IIstanbul University·Preclinical·NCT07802197·100 enrolled

Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT07292298·44 enrolled

Prospective Evaluation of Quality of Life and Utilities Following Surgical Treatment of Rectal Cancer

Recruiting·MM.D. Anderson Cancer Center·N/A·NCT02107105·430 enrolled

Short-Course Radiotherapy Combined With mFOLFOX6, PD-1 Antibody and Cetuximab (for RAS/BRAF Wild-Type)/Bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma: a Phase III Randomized Controlled Trial

Recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 3·NCT07549399·204 enrolled

Phase II Clinical Trial of FOLFOX, Botensilimab, Plus Balstilimab in Patients With Localized Rectal Cancer

Recruiting·CCity of Hope Medical Center·Phase 2·NCT06780787·26 enrolled

A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)

Recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT07669220·76 enrolled

Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT05108428·20 enrolled

Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma

Active, not recruiting·TThe First Affiliated Hospital of Anhui Medical University·Phase 2·NCT07127497·50 enrolled

Neoadjuvant Chemoradiotherapy and Immunotherapy Combined With Ketogenic Diet and/or High-Dose Intravenous Vitamin C in pMMR/MSS Locally Advanced Rectal Adenocarcinoma: A Prospective, Multicenter, Phase Ⅱ Clinical Study (CRI-KEV Trial)

Not yet recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT07765667·100 enrolled

ULtra sensiTive ctDNA-Informed Management eArly-stage recTal cancEr (ULTIMATE)

Not yet recruiting·UUniversity of California, Davis·Phase 2·NCT07209215·200 enrolled

Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)